INDO-GLOBAL ENT. | NIDAN LABORATORIES | INDO-GLOBAL ENT./ NIDAN LABORATORIES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -31.9 | - | - | View Chart |
P/BV | x | 1.4 | 0.6 | 238.9% | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
INDO-GLOBAL ENT. NIDAN LABORATORIES |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
INDO-GLOBAL ENT. Mar-20 |
NIDAN LABORATORIES Mar-23 |
INDO-GLOBAL ENT./ NIDAN LABORATORIES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 20 | 77 | 26.6% | |
Low | Rs | 20 | 31 | 66.8% | |
Sales per share (Unadj.) | Rs | 0 | 17.5 | 0.0% | |
Earnings per share (Unadj.) | Rs | -0.7 | 2.5 | -25.7% | |
Cash flow per share (Unadj.) | Rs | -0.7 | 4.8 | -13.7% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 11.1 | 50.0 | 22.2% | |
Shares outstanding (eoy) | m | 6.37 | 13.90 | 45.8% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 0 | 3.1 | - | |
Avg P/E ratio | x | -31.1 | 21.0 | -148.0% | |
P/CF ratio (eoy) | x | -31.1 | 11.2 | -277.6% | |
Price / Book Value ratio | x | 1.8 | 1.1 | 171.5% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 130 | 744 | 17.5% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 1 | 49 | 1.0% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 0 | 243 | 0.0% | |
Other income | Rs m | 0 | 33 | 0.0% | |
Total revenues | Rs m | 0 | 276 | 0.0% | |
Gross profit | Rs m | -1 | 68 | -2.1% | |
Depreciation | Rs m | 0 | 31 | 0.0% | |
Interest | Rs m | 1 | 22 | 3.1% | |
Profit before tax | Rs m | -2 | 48 | -4.5% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2 | 13 | 15.9% | |
Profit after tax | Rs m | -4 | 35 | -11.8% | |
Gross profit margin | % | 0 | 28.0 | - | |
Effective tax rate | % | -93.4 | 26.4 | -353.4% | |
Net profit margin | % | 0 | 14.6 | - |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 0 | 209 | 0.0% | |
Current liabilities | Rs m | 7 | 95 | 7.2% | |
Net working cap to sales | % | 0 | 46.7 | - | |
Current ratio | x | 0 | 2.2 | 0.3% | |
Inventory Days | Days | 0 | 626 | - | |
Debtors Days | Days | 0 | 906 | - | |
Net fixed assets | Rs m | 80 | 630 | 12.7% | |
Share capital | Rs m | 64 | 139 | 45.8% | |
"Free" reserves | Rs m | 7 | 555 | 1.3% | |
Net worth | Rs m | 71 | 694 | 10.2% | |
Long term debt | Rs m | 2 | 48 | 5.0% | |
Total assets | Rs m | 80 | 839 | 9.5% | |
Interest coverage | x | -2.1 | 3.2 | -66.9% | |
Debt to equity ratio | x | 0 | 0.1 | 49.2% | |
Sales to assets ratio | x | 0 | 0.3 | 0.0% | |
Return on assets | % | -4.4 | 6.9 | -63.4% | |
Return on equity | % | -5.9 | 5.1 | -115.9% | |
Return on capital | % | -2.0 | 9.5 | -21.1% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 0 | 0 | - | |
Fx outflow | Rs m | 0 | 0 | - | |
Net fx | Rs m | 0 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | -1 | 139 | -1.0% | |
From Investments | Rs m | NA | -30 | -0.0% | |
From Financial Activity | Rs m | 1 | -106 | -1.3% | |
Net Cashflow | Rs m | 0 | 3 | 0.0% |
Indian Promoters | % | 2.8 | 57.0 | 4.9% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 0.0 | - | |
FIIs | % | 0.0 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 97.2 | 43.0 | 226.2% | |
Shareholders | 543 | 2,844 | 19.1% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare INDO-GLOBAL ENT. With: APOLLO HOSPITALS DR. LAL PATHLABS METROPOLIS HEALTHCARE KIMS NARAYANA HRUDAYALAYA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | INDO-GLOBAL ENT. | NIDAN LABORATORIES |
---|---|---|
1-Day | -4.76% | -1.47% |
1-Month | 6.24% | 5.79% |
1-Year | -13.28% | -27.09% |
3-Year CAGR | -7.78% | -36.50% |
5-Year CAGR | -4.74% | -23.85% |
* Compound Annual Growth Rate
Here are more details on the INDO-GLOBAL ENT. share price and the NIDAN LABORATORIES share price.
Moving on to shareholding structures...
The promoters of INDO-GLOBAL ENT. hold a 2.8% stake in the company. In case of NIDAN LABORATORIES the stake stands at 57.0%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of INDO-GLOBAL ENT. and the shareholding pattern of NIDAN LABORATORIES.
Finally, a word on dividends...
In the most recent financial year, INDO-GLOBAL ENT. paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
NIDAN LABORATORIES paid Rs 0.0, and its dividend payout ratio stood at 0.0%.
You may visit here to review the dividend history of INDO-GLOBAL ENT., and the dividend history of NIDAN LABORATORIES.
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.